Crossmark

Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report

Crossref DOI link: https://doi.org/10.1186/s12885-018-4612-2

Published Online: 2018-06-28

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tori, Masayuki http://orcid.org/0000-0002-9547-414X
Shimo, Toshirou
License Information

Text and Data Mining valid from 2018-06-28
More Information

Article History

Received: 16 October 2017

Accepted: 20 June 2018

First Online: 28 June 2018

Ethics approval and consent to participate

: The case report was approved by Ethics Committee of Osaka Police Hospital (#879) and written informed consent obtained from the patient for publication of this case report and accompanying images.

: Written informed consent obtained from the patient for publication of this case report and the accompanying images.

: The authors declare they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.